Relapsed or refractory Hodgkin lymphoma - brentuximab vedotin - initial authority application form (PB205)

Use this form to apply for initial PBS-subsidised treatment with brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.

Page last updated: 18 June 2024.
QC 36591